However, some advances in the treatment of solid tumors are currently employing the ROR1 antigen as a critical target due to its high expression in tumor cells and relatively scarcity in normal tissues, as well as its presence in CSCs responsible for relapses and treatment resistance. Here, ROR1 is linked to neoplasm.